Neurology Search
Neurology Neurology
narcolepsy
NARCOLEPSY

Narcolepsy is a chronic neurologic sleep disorder wherein the patient have excessive daytime sleepiness and rapid eye movement sleep is dysregulated.

It affects 1 in 1000 individuals, with prevalence of about 0.04% of general population.
The exact cause remains unclear.
Studies suggest a combination of genetic predisposition, abnormal neurotransmitter functioning and abnormal immune modulation.
Symptoms include excessive daytime sleepiness, cataplexy, sleep paralysis, sleep-related hallucinations, automatic behavior, fragmented nocturnal sleep and insomnia.

Narcolepsy Patient Education

Patient Education

Patient Education

  • Educate the patients regarding their condition & its implications at the time of diagnosis
  • Regular consultation between the patient & physician is essential to help patients modify their lifestyle & provide optimal management
  • Family support can also improve the course of the disease by helping the patients overcome challenges
  • Inform family members, friends, & co-workers of the signs of narcoleptic spells to help patients lessen possible injuries
  • Advise patients on their activities & jobs
    • Avoid potentially dangerous activities such as operating motor vehicles & machines when feeling sleepy
    • Avoid shift-work, driving, transportation-related jobs, or any work which requires continuous attention for long hours with breaks

Adequate & Regular Nocturnal Sleep

  • Patient should have adequate & regular nocturnal sleep to avoid exacerbating excessive daytime sleepiness
  • Comply with a strict sleep schedule of at least 7-8 hours of sleep at night with a consistent bedtime & time of morning awakening
Editor's Recommendations
Most Read Articles
Fremanezumab: Sustained benefits across the board for refractory migraine
Pearl Toh, 03 Jul 2020
After treatment with fremanezumab, a difficult-to-treat patient population with treatment-resistant episodic or chronic migraine saw sustained benefits across a broad range of measures, according to multiple analyses of the FOCUS study released during the AHS 2020 Virtual Meeting.
Aducanumab in Alzheimer’s disease: Does it work?
Pearl Toh, 24 Jun 2020
While aducanumab significantly reduced clinical decline in individuals with early Alzheimer's disease (AD) in one randomized trial, no changes were seen in another identical study — rendering the role of aducanumab in AD inconclusive.
Ketogenic diet good for Parkinson's?
Elvira Manzano, 24 Oct 2018
New evidence showed that a high-fat, low-carbohydrate ketogenic diet could help improve symptoms in patients with Parkinson's disease (PD), so did a low-fat, high-carbohydrate diet.
Erenumab shows sustained efficacy in refractory migraine over 2 years
Pearl Toh, 01 Jul 2020
The CGRP* receptor blocker erenumab shows sustained efficacy in reducing migraine frequency over 2 years in a difficult-to-treat patient population with episodic migraine who had failed 2–4 prior preventive treatments, an interim analysis of the LIBERTY** open-label extension study shows.